Seagen (SGEN) Tops Q4 EPS by 3c

Seagen (NASDAQ: SGEN) reported Q4 EPS of $0.90, $0.03 better than the analyst estimate of $0.87. Revenue for the quarter came in at $601.29 million versus the consensus estimate of $583.22 million.

“In 2020, we generated record product revenues of more than $1 billion driven by successful launches of PADCEV and TUKYSA, as well as continued growth of ADCETRIS,” said Clay Siegall, Ph.D., President and Chief Executive Officer of Seagen. “These strong results are in addition to several significant business, regulatory and development accomplishments during the year. Looking ahead, we are focused on maximizing the global potential of our approved medicines, advancing our late-stage programs towards securing approvals of new products, and expanding our innovative early-stage pipeline. In collaboration with our partner Genmab we submitted a BLA for tisotumab vedotin to the FDA, positioning it to be our fourth commercial product. We are on track for several other milestones across our pipeline over the course of 2021, and are in a strong financial position to continue executing against our goals.”

For earnings history and earnings-related data on Seagen (SGEN) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• HeartCore Enterprises, Inc. (HTCR) Misses Q2 EPS by 185c
• Boost Run, Inc. (BRUN) Reports Q2 Revenue of $31.1M